Life sciences

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2020 Financial Results

Friday, July 10, 2020 - 10:41pm

OLDSMAR, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2020.

Key Points: 
  • OLDSMAR, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2020.
  • Consolidated revenues for the second quarter of fiscal 2020 were $7.87 million compared to $8.13 million for the second quarter of fiscal 2019, a 3% decrease.
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.
  • Besides being AABB accredited as a cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization.

Global Digital Pathology Market Assessment 2020-2025 - Market Expected to Cross $1.1 Trillion by 2025, with North America Growing at the Highest Rate

Friday, July 10, 2020 - 2:15pm

However, the high cost of digital pathology systems is expected to restrict market growth to a certain extent.

Key Points: 
  • However, the high cost of digital pathology systems is expected to restrict market growth to a certain extent.
  • By type, the human pathology segment accounted for the largest share of the digital pathology market in 2019.
  • On the basis of type, the global digital pathology market is segmented into human and veterinary pathology.
  • The human pathology segment accounted for the largest share of the digital pathology market in 2019.

Beroni Group to Supply COVID-19 Antibody Test Kit to Japan

Friday, July 10, 2020 - 2:30pm

Beroni will start with a supply of 100,000 test kits to be distributed by these two Japanese partners.

Key Points: 
  • Beroni will start with a supply of 100,000 test kits to be distributed by these two Japanese partners.
  • Jacky Zhang, Chairman and CEO of Beroni Group, said, We are very excited to be able to work with Forsitech and Standard Capital to provide antibody testing to the Japanese market on a broader scale.
  • We believe that the antibody testing is an effective means to quickly detect the spread of the COVID-19 virus and prevent massive outbreaks.
  • Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases.

Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19

Friday, July 10, 2020 - 1:30pm

Gilead has previously reported the safety and efficacy results in 53 patients hospitalized with severe COVID-19 who were receiving remdesivir treatment as part of the companys compassionate use program.

Key Points: 
  • Gilead has previously reported the safety and efficacy results in 53 patients hospitalized with severe COVID-19 who were receiving remdesivir treatment as part of the companys compassionate use program.
  • Additional analyses from the compassionate use program are being presented at the conference, including data on the use of remdesivir in pediatric patients and in pregnant and postpartum women.
  • GS-5734, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc. or its related companies.
  • For more information about Gilead, please visit the companys website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Amneal Launches Generic Fluphenazine Following ANDA Approval by FDA

Friday, July 10, 2020 - 1:00pm

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg. Fluphenazine Hydrochloride is the generic version of Prolixin for treatment of schizophrenia.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg. Fluphenazine Hydrochloride is the generic version of Prolixin for treatment of schizophrenia.
  • According to IQVIA, a leading healthcare data and analytics provider, U.S. annual sales for Fluphenazine Hydrochloride Tablets for the 12 months ended May 2020 were approximately $143 million.
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products.
  • The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Teva to Host Conference Call to Discuss Second Quarter 2020 Financial Results at 8 a.m. ET on August 5, 2020

Thursday, July 9, 2020 - 9:00pm

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter financial results on Wednesday August 5, 2020 at 7:00 a.m.

Key Points: 
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter financial results on Wednesday August 5, 2020 at 7:00 a.m.
  • Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m.
  • Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve peoples lives for more than a century.

Global Gene Therapy Industry

Thursday, July 9, 2020 - 4:00pm

US Gene Therapy Market Share (in %) by Company: 2019 & 2025

Key Points: 
  • US Gene Therapy Market Share (in %) by Company: 2019 & 2025
    Projections in US$ Thousand by Vector: 2020 to 2027
    Table 23: Gene Therapy Market in the United States by Vector:
    in US$ Thousand by Vector: 2020 to 2027
    Table 27: Gene Therapy Market in Canada: Percentage Share
    Breakdown of Sales by Vector for 2012, 2020, and 2027
    Table 28: Japanese Market for Gene Therapy: Annual Sales
    Table 29: Gene Therapy Market in Japan: Historic Sales Analysis
    Table 33: Chinese Gene Therapy Market by Vector: Percentage
    Breakdown of Sales for 2012, 2020, and 2027
    Table 35: Gene Therapy Market in Europe: A Historic Market
    Table 37: European Gene Therapy Market Estimates and Forecasts in US$ Thousand by Vector: 2020-2027
    Table 40: Gene Therapy Market in France by Vector: Estimates
    Table 42: French Gene Therapy Market Share Analysis by Vector:
    Table 43: Gene Therapy Market in Germany: Recent Past, Current
    Table 45: German Gene Therapy Market Share Breakdown by Vector:
    Table 48: Italian Gene Therapy Market by Vector: Percentage
    Breakdown of Sales for 2012, 2020, and 2027
    Table 49: United Kingdom Market for Gene Therapy: Annual Sales
    Table 50: Gene Therapy Market in the United Kingdom: Historic
    in US$ Thousand by Vector: 2020 to 2027
    Table 54: Gene Therapy Market in Spain: Percentage Share
    Breakdown of Sales by Vector for 2012, 2020, and 2027
    in US$ Thousand by Vector: 2020 to 2027
    Table 56: Gene Therapy Market in Russia by Vector: A Historic
    Forecasts in US$ Thousand by Vector: 2020-2027
    in US$ Thousand by Region/Country: 2020-2027
    Table 62: Gene Therapy Market in Asia-Pacific: Historic Market
    Table 64: Gene Therapy Market in Asia-Pacific by Vector:
    Table 67: Gene Therapy Market in Australia: Recent Past,
    Table 72: Gene Therapy Market in India: Percentage Share
    Breakdown of Sales by Vector for 2012, 2020, and 2027
    Table 73: Gene Therapy Market in South Korea: Recent Past,
    Table 76: Rest of Asia-Pacific Market for Gene Therapy: Annual
    Table 77: Gene Therapy Market in Rest of Asia-Pacific: Historic
    Breakdown of Sales by Region/Country: 2012, 2020, and 2027
    America in US$ Thousand by Vector: 2012-2019
    Table 84: Latin American Gene Therapy Market by Vector:
    Percentage Breakdown of Sales for 2012, 2020, and 2027
    Forecasts in US$ Thousand by Vector: 2020-2027
    Table 88: Gene Therapy Market in Brazil by Vector: Estimates
    Table 91: Gene Therapy Market in Mexico: Recent Past, Current
    and Projections in US$ Thousand by Vector: 2020 to 2027
    Forecasts in US$ Thousand by Region/Country: 2020-2027
    Forecasts in US$ Thousand by Vector: 2020 to 2027
    Table 102: Gene Therapy Market in the Middle East: Percentage
    Share Breakdown of Sales by Vector for 2012,2020, and 2027
    Table 103: Iranian Market for Gene Therapy: Annual Sales
    Table 104: Gene Therapy Market in Iran: Historic Sales Analysis
    in US$ Thousand by Vector: 2020-2027
    Arabia in US$ Thousand by Vector: 2012-2019
    Table 111: Saudi Arabian Gene Therapy Market by Vector:
    Percentage Breakdown of Sales for 2012, 2020, and 2027
    Table 112: Gene Therapy Market in the United Arab Emirates:
    Analysis in US$ Thousand by Vector: 2012-2019
    Table 115: Gene Therapy Market in Rest of Middle East: Recent
    Analysis in US$ Thousand by Vector: 2012-2019
    Projections in US$ Thousand by Vector: 2020 to 2027
    Table 119: Gene Therapy Market in Africa by Vector: A Historic

Global Biopreservation Market (2020 to 2025) - Rising Demand for Organ Transplants Presents Opportunities

Thursday, July 9, 2020 - 4:00pm

Based on type, the biopreservation media and equipment market is segmented into biopreservation media and biopreservation equipment.

Key Points: 
  • Based on type, the biopreservation media and equipment market is segmented into biopreservation media and biopreservation equipment.
  • While the biopreservation media segment accounted for the largest market share in 2019, biopreservation equipment segment is expected to register the highest growth during the forecast period.
  • By biospecimen, the human tissue samples segment dominated the global biopreservation media and equipment market in 2019.
  • Based on biospecimen, the biopreservation media and equipment market is segmented into human tissue samples, organs, stem cells and other biospecimens.

  Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance

Thursday, July 9, 2020 - 2:03pm

We strongly believe the world cannot tackle the growing threat of AMR without collaboration and that it will take a combination of prevention measures, responsible stewardship and innovative thinking to overcome existing obstacles.

Key Points: 
  • We strongly believe the world cannot tackle the growing threat of AMR without collaboration and that it will take a combination of prevention measures, responsible stewardship and innovative thinking to overcome existing obstacles.
  • The new AMR Action Fund gives us the vehicle to do that by investing in and stimulating a potentially stronger pipeline for antimicrobial medicines.
  • By 2050, it is estimated that AMR could claim as many as 10 million lives per year.
  • At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

National Association of Specialty Pharmacy Releases Agenda for Fifth Annual Specialty Pharmacy Law Conference

Thursday, July 9, 2020 - 2:00pm

WASHINGTON, July 9, 2020 /PRNewswire/ -- The National Association of Specialty Pharmacy (NASP), a nonprofit organization representing specialty pharmacy industry stakeholders, announced today the full agenda for the fifth Annual Specialty Pharmacy Law Conference.

Key Points: 
  • WASHINGTON, July 9, 2020 /PRNewswire/ -- The National Association of Specialty Pharmacy (NASP), a nonprofit organization representing specialty pharmacy industry stakeholders, announced today the full agenda for the fifth Annual Specialty Pharmacy Law Conference.
  • "NASP is thrilled to once again host our very popular Specialty Pharmacy Law Conference.
  • The Specialty Pharmacy Law Conference is a unique one-day event intended for general and in-house counsel for national and regional specialty pharmacies, manufacturers, practicing attorneys in health care law, compliance officers and executives.
  • Sessions include fraud, buying and selling a specialty pharmacy, issues on pharmacy benefit managers' radar, and effective compliance plans.